{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"345","value":"529"},{"groupId":"OG001","spread":"430","value":"300"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"OS is defined as the time from the date of study enrollment until time of death from any cause and was estimated using Kaplan-Meier curves along with a 95% confidence interval.","dispersionType":"Standard Deviation","groups":[{"description":"Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day on days 1-5 of each of six cycles.\n\nAvelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.","id":"OG000","title":"Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab"},{"description":"Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a second dose level of 2 mcg/kg/day on days 1-5 of each of six cycles.\n\nAvelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.","id":"OG001","title":"Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"From study opening through May 2022 when the study was completed with a maximum follow up of approximately 2 years and 11 months for any participant.","title":"Mean Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Days"}